Oncology Is Booming But Cost Outlook Is Grim, IMS Says
This article was originally published in The Pink Sheet Daily
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new IMS report.
You may also be interested in...
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.